Dylan A. Goodin

Dylan A. Goodin

Auto-generated profile, based on publicly available information

Dylan A. Goodin

Department of Bioengineering, University of Louisville, Louisville, Kentucky

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2022 in Immunology
Verified
Journal Article
Open access
DGDylan A. Goodin
Dylan A. Goodin
ECEric Chau
Eric Chau
ATAnjana Tiwari
Anjana Tiwari
Biana GodinBiana Godin
Biana Godin
Hermann FrieboesHermann Frieboes
Hermann Frieboes
Breast cancer liver metastases (BCLM) are usually unresectable and difficult to treat with systemic chemotherapy. A major reason for chemotherapy failure is that BCLM are typically small, avascular nodules, with poor transport and fast washout of therapeutics from surrounding capillaries. We have previously shown that nanoalbumin‐bound paclitaxel (nab‐PTX) encapsulated in porous silicon multistage nanovectors (MSV) is preferentially taken up by tumour‐associated macrophages (TAM) in the BCLM microenvironment. The TAM alter therapeutic transport characteristics and retain it in the tumour vicinity, increasing cytotoxicity. Computational modeling has shown that therapeutic regimens could be designed to eliminate single lesions. To evaluate clinically‐relevant scenarios, this study develops a modeling framework to evaluate MSV‐nab‐PTX therapy targeting multiple BCLM. An experimental model of BCLM, splenic injection of breast cancer 4 T1 cells was established in BALB/C mice. Livers were analyzed histologically to determine size and density of BCLM. The data were used to calibrate a 3D continuum mixture model solved via distributed computing to enable simulation of multiple BCLM. Overall tumour burden was analyzed as a function of metastases number and potential therapeutic regimens. The computational model enables realistic 3D representation of metastatic tumour burden in the liver, with the capability to evaluate BCLM growth and therapy response for hundreds of lesions. With the given parameter set, the model projects that repeated MSV‐nab‐PTX treatment in intervals <7 days would control the tumour burden. We conclude that nanotherapy targeting TAM associated with BCLM may be evaluated and fine‐tuned via 3D computational modeling that realistically simulates multiple metastases.

1 October 2024 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
DGDylan A. Goodin
Dylan A. Goodin
ECEric Chau
Eric Chau
JZJunjun Zheng
Junjun Zheng
COCailin O'Connell
Cailin O'Connell
ATAnjana Tiwari
Anjana Tiwari
Hermann FrieboesHermann Frieboes
Hermann Frieboes
Breast cancer liver metastases (BCLM) are hypovascular lesions that resist intravenously administered therapies and have grim prognosis. Immunotherapeutic strategies targeting BCLM critically depend on the tumor microenvironment (TME), including tumor-associated macrophages. However, a priori characterization of the BCLM TME to optimize therapy is challenging because BCLM tissue is rarely collected. In contrast to primary breast tumors for which tissue is usually obtained and histologic analysis performed, biopsies or resections of BCLM are generally discouraged due to potential complications. This study tested the novel hypothesis that BCLM TME characteristics could be inferred from the primary tumor tissue. Matched primary and metastatic human breast cancer samples were analyzed by imaging mass cytometry, identifying 20 shared marker clusters denoting macrophages (CD68, CD163, and CD206), monocytes (CD14), immune response (CD56, CD4, and CD8a), programmed cell death protein 1, PD-L1, tumor tissue (Ki-67 and phosphorylated ERK), cell adhesion (E-cadherin), hypoxia (hypoxia-inducible factor-1α), vascularity (CD31), and extracellular matrix (alpha smooth muscle actin, collagen, and matrix metalloproteinase 9). A machine learning workflow was implemented and trained on primary tumor clusters to classify each metastatic cluster density as being either above or below median values. The proposed approach achieved robust classification of BCLM marker data from matched primary tumor samples (AUROC ≥ 0.75, 95% confidence interval ≥ 0.7, on the validation subsets). Top clusters for prediction included CD68+, E-cad+, CD8a+PD1+, CD206+, and CD163+MMP9+. We conclude that the proposed workflow using primary breast tumor marker data offers the potential to predict BCLM TME characteristics, with the longer term goal to inform personalized immunotherapeutic strategies targeting BCLM. Significance: BCLM tissue characterization to optimize immunotherapy is difficult because biopsies or resections are rarely performed. This study shows that a machine learning approach offers the potential to infer BCLM characteristics from the primary tumor tissue.

3 November 2026 in Biophysics Reviews
Verified
Journal Article
Open access
WQWyatt Quinones
Wyatt Quinones
JHJackson Huse
Jackson Huse
DGDylan A. Goodin
Dylan A. Goodin
ZLZoe Lung
Zoe Lung
LTLandon Teer
Landon Teer
JCJoseph Chen
Joseph Chen
Cell migration is an essential biological process involved in development, wound healing, immune response, and cancer metastasis. Recent advances in imaging techniques in vivo have identified confined cell migration as a critical type of locomotion through tissues and vascular tracks. In particular, confined cell migration is crucial in cancer invasion and metastasis, as tumor infiltration necessitates cell migration through confined pores in tissue (1–20 μm) and vascular components (<5 μm). Although cell migration from a biological perspective has been extensively reviewed, recent developments in bioengineering tools such as three-dimensional in vitro models and computational modeling have opened new possibilities to study confined migration in normal development and in disease. This review focuses on in vitro bioengineered platforms and mathematical models developed to study the mechanisms of confined migration. We anticipate that further development of these bioengineered platform technologies, coupled with advances in computational modeling, including multi-scale models and machine learning, will be pivotal to facilitating mechanistic testing and evaluation of therapeutic strategies effectively targeting wound healing and cancer metastasis.


3 April 2025
Verified
Other
Open access
PDF file
DGDylan A. Goodin
Dylan A. Goodin
ECEric Chau
Eric Chau
JZJunjun Zheng
Junjun Zheng
COCailin O'Connell
Cailin O'Connell
ATAnjana Tiwari
Anjana Tiwari
Hermann FrieboesHermann Frieboes
Hermann Frieboes
S6. PLS-DA score plots of classifying BCLM patient IMC clusters into Low (

3 April 2025
Verified
Other
Open access
PDF file
DGDylan A. Goodin
Dylan A. Goodin
ECEric Chau
Eric Chau
JZJunjun Zheng
Junjun Zheng
COCailin O'Connell
Cailin O'Connell
ATAnjana Tiwari
Anjana Tiwari
Hermann FrieboesHermann Frieboes
Hermann Frieboes
S10. Variable importance for prediction of BCLM Collagen+, E-cad+, HIF1α+, and Ki-67+ using ML models.